Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032474 · ClinicalTrials.gov registry record · Phase 1
Ginkgo Biloba Extract and the Insulin Resistance Syndrome
A Phase 1 study of Type 2 Diabetes Mellitus, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00032474 is a Phase 1 study of Type 2 Diabetes Mellitus that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 150 participants, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00032474, a Phase 1 study of Type 2 Diabetes Mellitus, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether the ingestion of the herbal dietary supplement Ginkgo biloba extract has any effect on the efficacy of three classes of diabetic medications - (Glucotrol, Glucophage and Actose). Additionally, the study will examine the effect of Ginkgo biloba extract on pancreatic insulin production in non-diabetic subjects between the ages of 20 and 75 years old.
Conditions Studied
Interventions
- DRUG Ginkgo biloba extract
Study Locations (1)
Texas
- University of Texas Health Sciences Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2001-12 |
| Est. Completion | 2005-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032474
The ClinicalTrials.gov registry entry for NCT00032474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (95% lower). The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Ginkgo biloba extract is the first listed.
NCT00032474 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00032474 about?
NCT00032474 is a clinical study titled "Ginkgo Biloba Extract and the Insulin Resistance Syndrome". The purpose of this study is to examine whether the ingestion of the herbal dietary supplement Ginkgo biloba extract has any effect on the efficacy of three classes of diabetic medications - (Glucotrol, Glucophage and Actose). Additionally, the study will examine the effect of Ginkgo biloba extract ...
What is the current status of trial NCT00032474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2001-12. Estimated completion is 2005-05.
What conditions does trial NCT00032474 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00032474?
The interventions under investigation include: Ginkgo biloba extract (DRUG).
Who is sponsoring clinical trial NCT00032474?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00032474 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
COMPLETED · Phase 1
-
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
COMPLETED · Phase 1
-
A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol
COMPLETED · Phase 1
-
Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.